Application of the ADVIA cerebrospinal fluid assay to count residual red blood cells in blood components

Culibrk, Brankica; Stone, Earl J.; Levin, E.J.; Weiss, Sandra; Serrano, Katherine; Devine, Dana V.

doi:10.1111/j.1423-0410.2012.01601.x

Cited by 8 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the RBC content of each PC that was transfused during the study period was not quantified, quality control data from the participating centres indicated that the mean RBC content in PCs prepared from whole blood collections or obtained from apheresis devices was only 0·036 and 0·00043 ml, respectively (http://www.bancsang.net/en/professionals/resum_qualitat.html, last accessed 2 June 2014). These data, regarding the RBC content in PCs, are consistent with previous reports (Santana & Dumont, ; Culibrk et al , ). There is evidence that the minimum RBC volume necessary to elicit a primary anti‐D immune response is only 0·03 ml (Lozano & Cid, ), which is within the range of the quality control data from the centres in this study that transfused PCs prepared from whole blood collections.…”

Section: Discussionsupporting

confidence: 93%

Low frequency of anti‐D alloimmunization following D+ platelet transfusion: the Anti‐D Alloimmunization after D‐incompatible Platelet Transfusions (ADAPT) study

et al. 2014

View full text Add to dashboard Cite

Summary The reported frequency of D alloimmunization in D- recipients after transfusion of D+ platelets varies. This study was designed to determine the frequency of D alloimmunization, previously reported to be an average of 5%±2%. A primary anti-D immune response was defined as the detection of anti-D ≥28 days following the first D+ platelet transfusion. Data were collected on 485 D- recipients of D+ platelets in 11 centres between 2010-2012. Their median age was 60 (range 2-100) years. Diagnoses included: haematological (203/485, 42%), oncological (64/485, 13%) and other diseases (218/485, 45%). Only 7/485 (1.44%; 95%CI 0.58-2.97%) recipients had a primary anti-D response after a median serological follow-up of 77 days (range: 28-2111). There were no statistically significant differences between the primary anti-D formers and the other patients, in terms of gender, age, receipt of immunosuppressive therapy, proportion of patients with haematological/oncological diseases, transfusion of whole blood-derived or apheresis platelets or both, and total number of transfused platelet products. This is the largest study with the longest follow-up of D alloimmunization following D+ platelet transfusion. The low frequency of D alloimmunization should be considered when deciding whether to administer Rh Immune Globulin to D- males and D- females without childbearing potential after transfusion of D+ platelets.

show abstract

Section: Discussionsupporting

confidence: 93%

Low frequency of anti‐D alloimmunization following D+ platelet transfusion: the Anti‐D Alloimmunization after D‐incompatible Platelet Transfusions (ADAPT) study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…When counting very low levels of cells, misclassification of a few cells may be crucial. Conversely, if major numbers of cells are counted, then a few misclassifications are not of significance, as demonstrated in the study by Culibrk and colleagues, who successfully used the ADVIA 2120 to detect residual RBCs in plasma and platelet concentrates …”

Section: Discussionmentioning

confidence: 99%

Methods for counting residual leukocytes in leukocyte‐depleted plasma—a comparison between a routine hematology instrument, the Nageotte chamber, flow cytometry, and a fluorescent microscopy analyzer

Petersson

Ekblom

2017

Transfusion

View full text Add to dashboard Cite

show abstract

“…Interest in the use of hematology analyzers to count rRBCs was renewed by the latest generation of instruments being able to count low levels of cells in body fluids (BFs). Assessment of the cerebrospinal fluid (CSF) analysis mode on an ADVIA 120 hematology analyzer (Siemens, Berlin, Germany) found that although sample predilution was required for counting of rRBCs, the assay met the required performance characteristics 13 …”

Section: Introductionmentioning

confidence: 99%

Residual red cells in blood components: A multisite study of fully automated enumeration using a hematology analyzer

et al. 2020

View full text Add to dashboard Cite

Background Manufacture of platelet concentrates (PCs) and plasma may fail to remove all residual red blood cells (rRBCs). Measuring rRBCs for compliance to guidelines has proven challenging, leading to an absence of a consensus methodology. Sysmex hematology analyzers with the Blood Bank mode (BB mode) analysis option offer the potential for automated rRBC counting. We therefore performed a two‐site appraisal of the system. Study Design and Methods Performance characteristics were determined using platelet and plasma samples spiked with RBCs. Sample stability (n = 47) and the impact of sample type were also assessed. Components (platelets, n = 1474; plasma, n = 77) prepared using different routine manufacturing methods were tested to assess variation in rRBC concentration. Results Linearity studies up to 19 000 RBCs/μL demonstrated good correlation between expected and observed results (R2 ≥ 0.9731), and flow cytometric results also correlated well with BB mode (R2 = 0.9400). Precision analysis gave a limit of quantitation of 6 to 7 RBCs/μL, and carryover was 0.03%. Ethylenediaminetetraacetic acid and plain tube results were not significantly different (P ≥ 0.10), and samples were stable up to 24 hours. Apheresis PCs produced at two sites had lower rRBC concentrations (medians, 17 and 13 RBCs/μL) than those produced with the buffy coat method either manually (median, 681 RBCs/μL) or with the automated Terumo Automated Centrifuge and Separator Integration process (median, 81 RBCs/μL). All PCs failing visual inspection as having RBCs ≥4000 RBCs/μL were also detected by the BB mode. Conclusion The BB mode had acceptable performance characteristics and has the potential for integration into a fully automated process control system for rRBC enumeration in plasma and PCs.

show abstract

Application of the ADVIA cerebrospinal fluid assay to count residual red blood cells in blood components

Abstract: The ADVIA CSF assay is a sensitive, precise and accurate means to assess rRBC counts in non-RBC components.

Cited by 8 publications

References 17 publications

Low frequency of anti‐D alloimmunization following D+ platelet transfusion: the Anti‐D Alloimmunization after D‐incompatible Platelet Transfusions (ADAPT) study

Low frequency of anti‐D alloimmunization following D+ platelet transfusion: the Anti‐D Alloimmunization after D‐incompatible Platelet Transfusions (ADAPT) study

Methods for counting residual leukocytes in leukocyte‐depleted plasma—a comparison between a routine hematology instrument, the Nageotte chamber, flow cytometry, and a fluorescent microscopy analyzer

Residual red cells in blood components: A multisite study of fully automated enumeration using a hematology analyzer

Contact Info

Product

Resources

About